MAP2K7 and cancer: Given that chemoresistance to proteasome inhibitors is due to the survival of stem cell-like cancer cells that can undergo EMT51, MEK inhibitors may overcome recurrent tumors induced by proteasome inhibitors (Supplementary Fig. 7).